Drug Trial Radar · NCT05939700
Mavacamten Pregnancy Surveillance Program
Last checked: Nov 20, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Nov 9, 2023
Primary completion
Apr 30, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jul 11, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 15 years
Summary
As written by the sponsor on the registry.
The purpose of this observational pregnancy safety study is to assess maternal, fetal, and infant outcomes after exposure to mavacamten at any time during pregnancy and/or breastfeeding.
Conditions
- Breastfeeding
- Hypertrophic Cardiomyopathy
- Pregnancy Related
Interventions
MavacamtenDrug
Observational study of individuals exposed to at least 1 dose of mavacamten at any time during pregnancy and/or breastfeeding
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pregnancy outcomesTime frame: Up to 10 months
- Fetal/neonatal/infant outcomesTime frame: Up to 12 months post pregnancy outcome
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Mavacamten Pregnancy Surveillance Program, PPD Inc
Wilmington, North Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.